Company Overview
| Stock Name | 培力控股有限公司 |
|---|---|
| Stock Code | 01498 |
| Company Full Name | 培力控股有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要以「農本方」品牌從事研發、制造及銷售濃縮中藥配方顆粒產品及中藥保健品，并提供中醫門診服務。 |
| Listing Date | 2015-07-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港新界大埔香港科學園1期無線電中心2樓201-207單位 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.purapharm.com |
| Share Registrar | |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 5.98 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 127,607,220 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 3.83 |
|---|---|
| First Day Open | HK$ 4.77 |
| First Day Change | -35.95% |
| First Day Volume | 20735500.0 |
| First Day Turnover | 85492600.0 |
Use of Proceeds
| Use of Proceeds | 1、約30.0%或86.7百萬港元將用作擴建生產設施及為現有生產線進行升級； 2、約25.0%或72.2百萬港元將用作在香港及中國成立新的農本方?中醫診所； 3、約20.0%或57.8百萬港元用作擴展我們的分銷網絡至中國的新目標城市，主要透過與國藥控股合作付諸實行，包括：(i)為新客戶購買農本方?智能中醫診所管理及配藥系統設備（每個藥房系統的平均成本為150,000港元）；(ii)就農本方?智能中醫診所管理及配藥系統的運營及維護培訓新的分銷商及醫院員工；(iii)提供售后及維護服務；(iv)在中國的獲批準醫院及醫療機構成立及裝修我們從事直接銷售的中藥房； 4、約15.0%或43.3百萬港元用作為下列兩種新中成藥產品的開發及推廣（包括：(i)完成中國規定的臨床試驗；(ii)香港及中國的新產品注冊；及(iii)有關測試、抽樣及項目管理）提供資金； 5、約10.0%或28.9百萬港元將用作我們的營運資金及其他一般公司用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
BOCOM International (Asia) Limited CE API271
Overall Coordinators (1)
交银国际证券有限公司 CE APJ121
Joint Bookrunners (1)
交银国际证券有限公司 CE APJ121
Joint Lead Managers (2)
交银国际证券有限公司 CE APJ121
星展亚洲融资有限公司 CE AAE430
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 陳宇齡 |
|---|---|
| Company Secretary | 陳焯墁 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 陳宇齡及關連人士(55.41%) |
|---|
